Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 24, 2023.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Ahead of the 2024 MDA Conference, the vice president of public policy and advocacy at the Muscular Dystrophy Association talked about conference advocacy collaboration, access to treatments, and the state of healthcare. [WATCH TIME: 6 minutes]
The associate professor of clinical neurology at the University of Miami Miller School of Medicine talked about findings from a recent post hoc analysis assessing the FDA-approved treatment of midazolam for seizure clusters. [WATCH TIME: 3 minutes]
In this edition of NeuroVoices, the physician neurologist and neuroimmunologist at Cedars Sinai Medical Center discussed RNDS 2023, an educational event for Spanish-speaking patients with rare neuroimmune disorders.
In episode 5 of the "Novel Mechanisms of Action in Multiple Sclerosis: Focus on BTK Inhibitors" video series, Jiwon Oh, MD, PhD, FRCPC, provides an overview of phase II results of tolebrutinib for the treatment of multiple sclerosis.
The director of the headache section at Cleveland Clinic’s Neurological Institute gave an administrative perspective on the changes to how patients with migraine are cared for, led by significant developments in recent years. [WATCH TIME: 4 minutes]